Company
Kerecis
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
11
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Kerecis, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Kerecis.
Latest FDA decisions
The 8 newest of 11 since 2015.
- Kerecis Express (50250)510(k)
K260058 · Decided Oct 30, 2026 · 295 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
K251845 · Decided Jul 16, 2025 · 30 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
K251844 · Decided Jul 15, 2025 · 29 days after receipt
Device type: Mesh, Surgical, Collagen, Plastic And Reconstructive Surgery (OXH) · General & Plastic Surgery
8 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06073301 · 6 participants · Start Aug 1, 2023 · Primary completion Aug 1, 2025
Device: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT) · For: Necrotizing Fasciitis
Sites: Augusta, Georgia
NCT05898711 · 75 participants · Start Mar 25, 2022 · Primary completion Oct 29, 2024
Device: Fish skin graft · For: Surgery-Complications
Sites: Crystal Lake, Illinois; New York, New York; Greensboro, North Carolina · 4 sites in all
- Kerecis Real-World Fish Skin Graft RegistryEnrolling by invitation
NCT06384183 · 600 participants (planned) · Start Aug 7, 2024 · Primary completion Dec 2026
Device: Kerecis Fish Skin Graft · For: Wounds; Pressure Ulcer; Diabetic Foot Ulcer and 3 more
Sites: Sarasota, Florida; Greensboro, North Carolina; Beavercreek, Ohio · 5 sites in all
8 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.